UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study

Experimental and clinical endocrinology & diabetes, 2002-01, Vol.110 (1), p.10

2002

Volltextzugriff (PDF)

Length of Hospital Stay and Associated Costs for Olanzapine vs. Haloperidol in the Treatment of Schizophrenia Relapse in Germany

The European journal of health economics, 2003, Vol.4 (2), p.85-89

2003

Volltextzugriff (PDF)

Krankheitskosten von COPD in Deutschland

Pneumologie (Stuttgart, Germany), 2004-12, Vol.58 (12), p.837-844

2004

Volltextzugriff (PDF)

Cost-of-illness Study for the Treatment of COPD in Germany

Pneumologie (Stuttgart, Germany), 2004-12, Vol.58 (12), p.837-844

2004

Volltextzugriff (PDF)

Costs of type 2 diabetes in Germany. Results of the CODE-2 study

Deutsche medizinische Wochenschrift, 2001-05, Vol.126 (20), p.585-589

2001

Volltextzugriff (PDF)

PRS15 OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA

Value in health, 2005-11, Vol.8 (6), p.A215-A216

2005

Volltextzugriff (PDF)

Kosteneffektivitätsanalyse der Therapie der COPD mittels Tiotropium, Salmeterol und Ipratropium in Deutschland

Pneumologie, 2004, Vol.58 (S 1)

2004

Volltextzugriff (PDF)

PMH24 GEO OBSERVATIONAL STUDY: 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

Value in health, 2005-11, Vol.8 (6), p.A203-A203

2005

Volltextzugriff (PDF)

PMH2 GEO OBSERVATIONAL STUDY: 12 MONTH'S DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

Value in health, 2004-11, Vol.7 (6), p.776-776

2004

Volltextzugriff (PDF)

PGI3 COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY

Value in health, 2004-11, Vol.7 (6), p.754-754

2004

Volltextzugriff (PDF)

Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study

Medizinische Klinik (München. 1983), 2002-12, Vol.97 (12), p.713-719

2002

Volltextzugriff (PDF)

PIN42 MEASURING TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING FROM PRIMARY ANTIBODY DEFICIENCIES

Value in health, 2003-11, Vol.6 (6), p.761-761

2003

Volltextzugriff (PDF)

PRP13 COSTS OF COPD IN GERMANY—RESULTS OF A COST-OF ILLNESS STUDY

Value in health, 2003-11, Vol.6 (6), p.781-781

2003

Volltextzugriff (PDF)

Hospitalisation and costs for schizophrenia relapse treatment in Germany

European psychiatry, 2002-05, Vol.17, p.151-151

2002

Volltextzugriff (PDF)

Bootstrap Confidence Intervals for Costs-of-Illness of Type 2 Diabetes Mellitus in Germany

Value in health, 2002-09, Vol.5 (5), p.398-404

2002

Volltextzugriff (PDF)

Kosten des Typ-2-Diabetes in Deutschland

Deutsche medizinische Wochenschrift, 2001, Vol.126 (20), p.585-589

2001

Volltextzugriff (PDF)

PIN16 ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP)

Value in health, 2004-11, Vol.7 (6), p.762-763

2004

Volltextzugriff (PDF)

DB3 COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY

Value in health, 2003-11, Vol.6 (6), p.607-607

2003

Volltextzugriff (PDF)

PDG16: BUDGETARY IMPACT OF TREATMENT GUIDELINES—THE EXAMPLE OF TYPE 2 DIABETES

Value in health, 2001-09, Vol.4 (6), p.508-508

2001

Volltextzugriff (PDF)

PDG13: ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY—AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES

Value in health, 2001-09, Vol.4 (6), p.507-507

2001

Volltextzugriff (PDF)

PMH12 PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY

Value in health, 2002-11, Vol.5 (6), p.518-519

2002

Volltextzugriff (PDF)

PMH11 ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY

Value in health, 2002-11, Vol.5 (6), p.518-518

2002

Volltextzugriff (PDF)

PDB3: USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES

Value in health, 2000-09, Vol.3 (5), p.338-339

2000

Volltextzugriff (PDF)

PDB1: RESOURCE USE AND COST ASSOCIATED WITH MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES

Value in health, 2000-03, Vol.3 (2), p.135-135

2000

Volltextzugriff (PDF)

PEN4: MEASURING THE REAL ANNUAL DIRECT COSTS OF DIABETES TYPE 2 PATIENTS IN GERMANY

Value in health, 1999-09, Vol.2 (5), p.395-395

1999

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(42)
Tagungsberichte
(2)

Sprache

Englisch
(32)
Deutsch
(12)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(9)
Physical Sciences
(8)
Exact Sciences And Technology
(7)
Adult
(6)
Polymer Science
(6)
Aged
(5)
Antioxidants
(5)
Applied Sciences
(5)
Female
(5)
Germany
(5)
Middle Aged
(5)
Aged, 80 And Over
(4)
Degradation
(4)
Diabetes Mellitus, Type 2 - Economics
(4)
Life Sciences & Biomedicine
(4)
Male
(4)
Oxidation
(4)
Polyethylene
(4)
Polyethylenes
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study

Length of Hospital Stay and Associated Costs for Olanzapine vs. Haloperidol in the Treatment of Schizophrenia Relapse in Germany

Krankheitskosten von COPD in Deutschland

Cost-of-illness Study for the Treatment of COPD in Germany

Costs of type 2 diabetes in Germany. Results of the CODE-2 study

PRS15 OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA

Kosteneffektivitätsanalyse der Therapie der COPD mittels Tiotropium, Salmeterol und Ipratropium in Deutschland

PMH24 GEO OBSERVATIONAL STUDY: 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

PMH2 GEO OBSERVATIONAL STUDY: 12 MONTH'S DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

PGI3 COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY

Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study

PIN42 MEASURING TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING FROM PRIMARY ANTIBODY DEFICIENCIES

PRP13 COSTS OF COPD IN GERMANY—RESULTS OF A COST-OF ILLNESS STUDY

Hospitalisation and costs for schizophrenia relapse treatment in Germany

Bootstrap Confidence Intervals for Costs-of-Illness of Type 2 Diabetes Mellitus in Germany

Kosten des Typ-2-Diabetes in Deutschland

PIN16 ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP)

DB3 COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY

PDG16: BUDGETARY IMPACT OF TREATMENT GUIDELINES—THE EXAMPLE OF TYPE 2 DIABETES

PDG13: ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY—AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES

PMH12 PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY

PMH11 ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY

PDB3: USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES

PDB1: RESOURCE USE AND COST ASSOCIATED WITH MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES

PEN4: MEASURING THE REAL ANNUAL DIRECT COSTS OF DIABETES TYPE 2 PATIENTS IN GERMANY

Suchergebnisse filtern